Full Text View
Tabular View
No Study Results Posted
Related Studies
CVD Risk and Health in Postmenopausal Phytoestrogen Users
This study has been completed.
First Received: October 27, 1999   Last Updated: January 3, 2006   History of Changes
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Information provided by: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT00000613
  Purpose

To determine the acceptability and benefits of use of a dietary supplement of the phytoestrogen, genistein, versus placebo on heart disease risk factors, bone density, and psychosocial outcomes in postmenopausal women.


Condition Intervention Phase
Bone Diseases
Cardiovascular Diseases
Coronary Disease
Depression
Heart Diseases
Myocardial Ischemia
Osteoporosis
Postmenopause
Behavioral: dietary supplements
Drug: genistein
Behavioral: diet, soy proteins
Phase II

Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: April 1997
Estimated Study Completion Date: December 2004
Detailed Description:

BACKGROUND:

Estrogen replacement therapy is beneficial for heart disease risk factors as well as for bone density. However, a large proportion of postmenopausal women are not compliant with therapeutic regimens. Phytoestrogens are naturally occurring compounds found in plants and soy products that have estrogenic effects, and may represent an alternative treatment for the prevention of heart disease and osteoporosis in postmenopausal women. However, few intervention trials have examined the extent to which it is possible to improve heart disease risk factors, bone density, and quality of life in postmenopausal women through use of a dietary supplement of phytoestrogen.

DESIGN NARRATIVE:

Randomized, double-blind, placebo-controlled study. A total of 210 women were enrolled in the study to be followed for one to two years. The women were randomized to phytoestrogen treatment or to placebo. Data are collected at baseline visits, at one and three month follow-up telephone calls, and at 6, 12, and 24 month follow-up clinic visits. Measures of high density lipoprotein and other heart disease risk factors, hip and spine bone density, and depression, life satisfaction, and quality of well-being are obtained. Cross-sectional and longitudinal comparisons of treatment and placebo groups are performed before and after adjustment and stratification for potentially confounding covariates.

The study was renewed in March 2002 to assess whether the women treated with phytoestrogens had lowered homocysteine, interleukin-6, C-reactive protein, E-selectin, and decreased obesity and fat mass over two years.

  Eligibility

Ages Eligible for Study:   45 Years to 74 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Postmenopausal women, ages 45 to 74.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000613

Sponsors and Collaborators
Investigators
Investigator: Donna Kritz-Silverstein University of California, San Diego
  More Information

Publications:
Study ID Numbers: 116
Study First Received: October 27, 1999
Last Updated: January 3, 2006
ClinicalTrials.gov Identifier: NCT00000613     History of Changes
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Anticarcinogenic Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myocardial Ischemia
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Arteriosclerosis
Protein Kinase Inhibitors
Bone Diseases
Hormones
Pathologic Processes
Musculoskeletal Diseases
Mental Disorders
Therapeutic Uses
Phytoestrogens
Cardiovascular Diseases
Arterial Occlusive Diseases
Estrogens
Heart Diseases
Depression
Vascular Diseases
Osteoporosis
Enzyme Inhibitors
Bone Diseases, Metabolic
Ischemia
Depressive Disorder
Protective Agents
Pharmacologic Actions
Behavioral Symptoms
Coronary Disease

ClinicalTrials.gov processed this record on November 27, 2009